Madrigal pharmaceuticals to present secondary analyses of data from phase 2 nash study of resmetirom and symposium at the digital international liver congress™ 2020

Conshohocken, pa., aug. 26, 2020 (globe newswire) -- madrigal pharmaceuticals, inc. (nasdaq:mdgl) announced today that on friday, august 28, 2020 at the digital international liver congress™ 2020, european association for the study of the liver (easl), secondary analyses of data from its phase 2 nash study with mgl-3196 (resmetirom) will be presented. resmetirom is currently in phase 3 development for the treatment of nash patients with stage 2-3 fibrosis ( clinicaltrials.gov nct03900429 and clinicaltrials.gov/nct04197479 ).
MDGL Ratings Summary
MDGL Quant Ranking